<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        133-334-10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GRANITRON 1MG-ML SOLUTION FOR Injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        GRANISETRON
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        130.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hikma Farmaceutica" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hikma Farmaceutica
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A04AA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Granitron contains a medicine called granisetron. This belongs to a group of medicines called &lsquo;5-HT3 receptor antagonists&rsquo; or &lsquo;antiemetics&rsquo;.</p><p>&nbsp;</p><p>Granitron is used to prevent or treat nausea (feeling sick) and vomiting (being sick) caused by other medical treatments, such as chemotherapy or radiotherapy for cancer, and by surgery.</p><p>&nbsp;</p><p>The solution for injection or infusion is for use in adults, adolescents and children from 2 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Granitron should not be given </strong></p><ul><li>&nbsp; &nbsp; If you are allergic (hypersensitive) to granisetron or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>&nbsp;</p><p>&nbsp;<strong>Warnings and precautions</strong></p><p>Talk to your doctor, nurse or pharmacist before using Granitron.</p><p>&nbsp;</p><p>Check with your doctor, nurse or pharmacist before using Granitron if you:</p><ul><li>&nbsp; &nbsp; Have problems with your bowel movements because of a blockade of your gut (intestines)</li><li>&nbsp; &nbsp; Have heart problems, are being treated for cancer with a medicine that is known to damage your heart or have problems with levels of salts, such as potassium, sodium or calcium in your body (electrolyte abnormalities)</li><li>&nbsp; &nbsp; Are taking other &lsquo;5-HT3 receptor antagonist&rsquo; medicines. These include dolasetron and ondansetron used like Granitron in the treatment and prevention of nausea and vomiting.</li></ul><p>&nbsp;</p><p>Serotonin syndrome is an uncommon but potentially life-threatening reaction that can occur with granisetron (see section 4). The reaction can occur if you take granisetron alone but it is more likely to occur if you take granisetron with certain other medicines (in particular fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, venlafaxine, duloxetine).</p><p>&nbsp;</p><p><strong>Other medicines and Granitron</strong></p><p>Please tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other medicines. This is because Granitron can affect the way some medicines work. Also some other medicines can affect the way this injection or infusion works.</p><p>&nbsp;</p><p>In particular, tell your doctor, nurse or pharmacist if you are taking the following medicines:</p><ul><li>&nbsp; &nbsp; Medicines used to treat an irregular heartbeat or other &lsquo;5-HT3 receptor antagonist&rsquo; medicines such as dolasetron or ondansetron (see &lsquo;Warnings and precautions&rsquo; above)</li><li>&nbsp; &nbsp; Phenobarbital, a medicine used to treat epilepsy.</li><li>&nbsp; &nbsp; SSRIs (selective serotonin reuptake inhibitors) used to treat depression and/or anxiety. Examples are fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram.</li><li>&nbsp; &nbsp; SNRIs (serotonin noradrenaline reuptake inhibitors) used to treat depression and/or anxiety. Examples are venlafaxine, duloxetine.</li></ul><p>&nbsp;</p><p><strong>Pregnancy and breastfeeding</strong></p><p>You should not have this injection or infusion if you are pregnant, trying to get pregnant or are breastfeeding, unless your doctor has told you to.</p><p>&nbsp;</p><p>If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor, nurse or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Granitron is not likely to affect your ability to drive or use any tools or machines.</p><p>&nbsp;</p><p><strong>Granitron contains sodium</strong></p><p>Granitron contains sodium. Each ml of Granitron 1 mg/1 ml Concentrate for Solution for Injection/Infusion contains 0.154 mmol (3.542 mg) sodium. This medicine contains less than 1 mmol sodium (23 mg) per ampoule, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p><p>Granitron contains sodium. Each 3 ml of Granitron 3 mg/3 ml Concentrate for Solution for Injection/Infusion contains 0.462 mmol (10.626 mg) sodium. This medicine contains less than 1 mmol sodium (23 mg) per ampoule, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;The injection or infusion will be given to you by a doctor or nurse. The dose of Granitron varies from one patient to another. It depends on your age, weight, and whether you are being given the medicine to prevent, or treat, nausea and vomiting. The doctor will work out how much to give you.</p><p>&nbsp;</p><p>Granitron can be given as an injection or infusion into the veins (intravenous).</p><p>&nbsp;</p><p><strong>Dosage</strong></p><p>The usual doses are:</p><p><em>Prevention of feeling or being sick following radio- or chemotherapy</em></p><p>You will be given the injection or infusion before your radio- or chemotherapy starts. The injection or infusion into your veins will take between 30 seconds (injection) and 5 minutes (infusion) and the dose will usually be between 1 and 3 mg. The medicine may be diluted before it is injected.</p><p>&nbsp;</p><p><em>Treatment of feeling or being sick following radio- or chemotherapy</em></p><p>The injection or infusion will take between 30 seconds (injection) and 5 minutes (infusion) and the dose will usually be between 1 and 3 mg. The medicine may be diluted before it is injected or infused into your veins. You may be given more injections or infusions to stop your sickness after the first dose. There will be at least 10 minutes between each dose. The most Granitron you will be given is 9 mg a day.</p><p>&nbsp;</p><p><em>Combination with steroids</em></p><p>The effect of the injection or infusion may be improved by the use of medicines called adrenocortical steroids. The steroid will be given either as a dose between 8 and 20 mg dexamethasone before your radio- or chemotherapy or as 250 mg methyl-prednisolone, which will be given both before and after your radio- or chemotherapy.</p><p>&nbsp;</p><p><em>Use in children in the prevention or treatment of feeling or being sick following chemotherapy</em></p><p>Children will be given Granitron by infusions into a vein as described above with the dose depending on the child&rsquo;s weight. The infusions will be diluted and be given before chemotherapy and will take 5 minutes. Children will be given a maximum of 2 doses a day, at least 10 minutes apart.</p><p>&nbsp;</p><p><em>Treatment of feeling or being sick following surgery </em></p><p>The injection into your veins will take between 30 seconds and 5 minutes and the dose will usually be 1 mg. The most Granitron you will be given is 3 mg a day.</p><p>&nbsp;</p><p><em>Use in children in the prevention or treatment of feeling or being sick following surgery </em></p><p>Children should not be given this injection to treat sickness or the feeling of sickness after surgery.</p><p>&nbsp;</p><p><strong>If you are given more Granitron than you should</strong></p><p>Because the injection or infusion will be given to you by a doctor or nurse, it is unlikely that you will be given too much. However, if you are worried talk to your doctor or nurse. Symptoms of overdose include mild headaches.</p><p>You will be treated depending on your symptoms.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.</p><p>&nbsp;</p><p>For information intended for healthcare professionals please see accordant section below.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>If you notice the following problem you must see a doctor straight away:</p><ul><li>&nbsp; &nbsp; Allergic reactions (anaphylaxis). The signs may include swelling of the throat, face, lips and mouth, difficulty in breathing or swallowing.</li></ul><p>&nbsp;</p><p><strong><em>Other side effects that may be experienced while taking this medicine are:</em></strong></p><p><strong>Very common (affects more than 1 user in 10):</strong></p><ul><li>&nbsp; &nbsp; Headache</li><li>&nbsp; &nbsp; Constipation. Your doctor will monitor your condition.</li></ul><p>&nbsp;</p><p><strong>Common (affects up to 1 in 10 users):</strong></p><ul><li>&nbsp; &nbsp; Difficulty in sleeping (insomnia)</li><li>&nbsp; &nbsp; Diarrhoea</li><li>&nbsp; &nbsp; Changes in how your liver is working shown by blood tests.</li></ul><p>&nbsp;</p><p><strong>Uncommon (affects up to 1 in 100 users):</strong></p><ul><li>&nbsp; &nbsp; Skin rashes or an allergic skin reaction or &ldquo;nettle-rash&rdquo; or &ldquo;hives&rdquo; (urticaria). The signs may include red, raised itchy bumps.</li><li>&nbsp; &nbsp; Abnormal involuntary movements, such as shaking, muscle rigidity and muscle contractions</li><li>&nbsp; &nbsp; Changes in the heartbeat (rhythm) and changes seen on ECG readings (electrical recordings of the heart)</li><li>&nbsp; &nbsp; Serotonin Syndrome. The signs may include diarrhoea, nausea, vomiting, high temperature and blood pressure, excessive sweating and rapid heartbeat, agitation, confusion, hallucination, shivering, muscles shakes, jerks or stiffness, loss of coordination and restlessness.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in original package in order to protect from light.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice the solution is not clear or free from particles.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Granitron contains</strong></p><p>The active substance<strong> </strong>is granisetron hydrochloride.</p><p>&nbsp;</p><p>Each ml of Granitron 1 mg/ml Concentrate for Solution for Injection/Infusion contains 1.12 mg granisetron hydrochloride equivalent to 1 mg granisetron.</p><p>&nbsp;</p><p>Each 3 ml of Granitron 3 mg/3 ml Concentrate for Solution for Injection/Infusion contains 3.36 mg granisetron hydrochloride equivalent to 3 mg granisetron.</p><p>&nbsp;</p><p>The other ingredients are sodium chloride, citric acid, hydrochloric acid, sodium hydroxide and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Granitron 1 mg/1 ml Concentrate for Solution for Injection/Infusion is a clear and colorless solution in type I clear sealed glass ampoules with blue one point cut (OPC). 

Pack size: 5 Ampoules (1 ml). 

Granitron 3 mg/3 ml Concentrate for Solution for Injection/Infusion is a clear and colorless solution in type I clear sealed glass ampoules with orange one point cut (OPC).   

Pack size: 5 Ampoule (3 ml). 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder </strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Hikma Farmaceutica (Portugal), S.A.</p><p>Estrada do Rio Da M&oacute;,</p><p>n.&deg;8, 8A e 8B, Ferven&ccedil;a</p><p>2705-906 Terrugem</p><p>Sintra, Portugal</p><p>Tel: + (351-2) 19608410</p><p>Fax: + (351-2) 19615102</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below).&nbsp; By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>&nbsp; &nbsp; Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>&nbsp;</strong></p><ul><li>&nbsp; &nbsp; Other GCC States</li></ul><p>Please contact the relevant competent authority. &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 02/2023; version number SA1.1.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي جرانيترون على دواء يسمى جرانيسيترون. ينتمي هذا الدواء إلى مجموعة من الأدوية تسمى &rsquo;مضادات مستقبلات 5HT3&lsquo; أو &rsquo;مضادات القيء&lsquo;.</p><p>&nbsp;</p><p dir="RTL">يستخدم جرانيترون لمنع أو علاج الغثيان (الشعور بالإعياء) والقيء (الإعياء) الذي تسببه العلاجات الطبية الأخرى، مثل العلاج الكيميائي أو العلاج الإشعاعي للسرطان، والجراحة.</p><p>&nbsp;</p><p dir="RTL">يستخدم محلول الحقن أو التسريب لدى البالغين، المراهقين والأطفال من عمر سنتين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم إعطاء جرانيترون</strong></p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;إذا كنت تعاني من حساسية (فرط الحساسية) لجرانيسيترون أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6).</li></ul><p>&nbsp;</p><p dir="RTL">&nbsp;<strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">تحدث مع طبيبك، الممرض أو الصيدلي قبل استخدام جرانيترون.</p><p>&nbsp;</p><p dir="RTL">تحقق من طبيبك، الممرض أو الصيدلي قبل استخدام جرانيترون إذا:</p><ul dir="rtl"><li>&nbsp; &nbsp; كان لديك مشاكل في حركات الأمعاء بسبب إحصار في القناة الهضمية (الأمعاء)</li><li>&nbsp; &nbsp; كنت تعاني من مشاكل في القلب أو تُعالج من السرطان بدواء يُعرف بإلحاق الضرر بقلبك أو لديك مشاكل في مستويات الأملاح، مثل البوتاسيوم، الصوديوم أو الكالسيوم في جسمك (اضطرابات الكهارل)</li><li>&nbsp; &nbsp; تتناول أدوية أخرى من &rsquo;مضادات مستقبلات 5HT3&lsquo;. تشمل هذه الأدوية دولاسيترون وأوندانسيترون التي تستخدم مثل جرانيترون في علاج الغثيان والقيء والوقاية منه.</li></ul><p dir="RTL">متلازمة سيروتونين هي تفاعل غير شائع ولكنه قد يهدد الحياة ويمكن أن يحدث مع جرانيسيترون (انظر القسم 4). يمكن أن يحدث التفاعل إذا كنت تتناول جرانيسيترون بمفرده ولكن من المرجح أن يحدث إذا كنت تتناول جرانيسيترون مع تناولك لبعض الأدوية الأخرى (على وجه الخصوص فلوكستين، باروكستين، سيرترالين، فلوفوكسامين، سيتالوبرام، إسيتالوبرام، فينلافاكسين، دولوكستين).</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وجرانيترون</strong></p><p dir="RTL">يُرجى إخبار طبيبك، الممرض أو الصيدلي إذا كنت تتناول، تناولت مؤخراً، أو قد تتناول أية أدوية أخرى. ذلك لأن جرانيترون يمكن أن يؤثر على طريقة عمل بعض الأدوية. كما يمكن أن تؤثر بعض الأدوية الأخرى على طريقة عمل هذا الحقن أو التسريب.</p><p>&nbsp;</p><p dir="RTL">على وجه الخصوص، أخبر طبيبك، الممرض أو الصيدلي إذا كنت تتناول الأدوية التالية:</p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;الأدوية المستخدمة لعلاج عدم انتظام ضربات القلب أو أدوية أخرى من &rsquo;مضادات مستقبلات 5HT3&lsquo; مثل دولاسيترون أو أوندانسيترون (انظر &rsquo;الاحتياطات والتحذيرات&lsquo; أعلاه)</li><li>&nbsp; &nbsp; &nbsp;فينوباربيتال، دواء يستخدم في علاج الصرع.</li><li>&nbsp; &nbsp; &nbsp;مثبطات استرداد السيروتونين الانتقائية المستخدمة في معالجة الاكتئاب و/أو القلق. ومن الأمثلة فلوكستين، باروكستين، سيرترالين، فلوفوكسامين، سيتالوبرام، إسكيتالوبرام.</li><li>&nbsp; &nbsp; &nbsp;مثبطات استرداد السيروتونين والنورأدرينالين المستخدمة في علاج الاكتئاب و/أو القلق. من الأمثلة على ذلك فينلافاكسين، دولوكستين.</li></ul><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">لا يجب أن تأخذي هذا الحقن أو التسريب إذا كنتِ حاملاً أو تحاولين أن تصبحي حاملاً أو كنتِ مرضعاً، إلا إذا أخبرك طبيبك بذلك.</p><p>&nbsp;</p><p dir="RTL">اطلبي النصيحة من طبيبك، الممرض أو الصيدلي قبل استخدام هذا الدواء إذا كنت حاملاً أو مرضعاً، تعتقدين بأنك حاملاً أو تخططين لذلك.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لن يؤثر جرانيترون، على الأرجح، على قدرتك على القيادة أو استخدام أي أدوات أو آلات.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي جرانيترون على الصوديوم </strong></p><p dir="RTL">يحتوي جرانيترون على الصوديوم. يحتوي كل مللتر من جرانيترون 1 ملغم/مللتر مركز للتخفيف للحقن/للتسريب على 0.154 ملمول (3.542 ملغم) صوديوم. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل أمبولة، وبذلك يمكن اعتباره &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي جرانيترون على الصوديوم. يحتوي كل 3 مللتر من جرانيترون 3 ملغم/3 مللتر مركز للتخفيف للحقن/للتسريب على 0.462 ملمول (10.626 ملغم) صوديوم. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل أمبولة، وبذلك يمكن اعتباره &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;سيتم إعطاؤك الحقن أو التسريب من قِبل الطبيب أو الممرض. تختلف جرعة جرانيترون من مريض لآخر. يعتمد ذلك على عمرك، وزنك وما إذا كنت تأخذ دواء لمنع الغثيان والقيء أو علاجهما. سيحدد الطبيب المقدار الذي يناسبك.</p><p>&nbsp;</p><p dir="RTL">يمكن إعطاء جرانيترون عن طريق الحقن أو التسريب في الأوردة (وريدي).</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">الجرعات المعتادة هي:</p><p dir="RTL"><em>الوقاية من الشعور بالإعياء أو التقيؤ بعد العلاج الإشعاعي أو الكيميائي</em></p><p dir="RTL">سيتم إعطاؤك الحقن أو التسريب قبل بدء العلاج الإشعاعي أو الكيميائي. سيستغرق الحقن أو التسريب في الأوردة ما بين 30 ثانية (الحقن) و5 دقائق (التسريب) وستتراوح الجرعة عادةً بين 1 و3 ملغم. يمكن تخفيف الدواء قبل حقنه.</p><p>&nbsp;</p><p dir="RTL"><em>علاج الشعور بالإعياء أو التقيؤ بعد العلاج الإشعاعي أو الكيميائي</em></p><p dir="RTL">سيستغرق الحقن أو التسريب ما بين 30 ثانية (الحقن) و5 دقائق (التسريب) وستكون الجرعة عادةً بين 1 و3 ملغم. يمكن تخفيف الدواء قبل حقنه أو تسريبه في أوردتك. قد يتم إعطاؤك المزيد من الحقن أو التسريب للتعافي من إعيائك بعد الجرعة الأولى. سيوجد فاصل زمني بين كل جرعة وأخرى لا يقل عن 10 دقائق. أكبر جرعة جرانيترون ستُعطى لك هي 9 ملغم يومياً.</p><p>&nbsp;</p><p dir="RTL"><em>إعطاء الدواء في توليفة مع الستيرويدات </em></p><p dir="RTL">يمكن تحسين تأثير الحقن أو التسريب باستخدام أدوية تسمى ستيرويدات قشرية كظرية. سيتم إعطاء الستيرويد إما بجرعة تتراوح بين 8 و20 ملغم ديكساميثازون قبل العلاج الإشعاعي أو الكيميائي أو 250 ملغم ميثيل بريدنيزولون، التي سيتم إعطاؤها قبل العلاج الإشعاعي أو الكيميائي وبعده.</p><p>&nbsp;</p><p dir="RTL"><em>يستخدم لدى الأطفال للوقاية من الإعياء أو التقيؤ أو معالجته بعد العلاج الكيميائي</em></p><p dir="RTL">سيُعطى الأطفال جرانيترون عن طريق التسريب في الوريد كما هو موصوف أعلاه على أن تحدد الجرعة حسب وزن الطفل. سيتم تخفيف التسريب ويُعطى قبل العلاج الكيميائي وسيستغرق 5 دقائق. سيتم إعطاء الأطفال جرعتين بحد أقصى يومياً، يفصل بينهما 10 دقائق على الأقل.</p><p>&nbsp;</p><p dir="RTL"><em>علاج الإعياء أو التقيؤ بعد الجراحة </em></p><p dir="RTL">سيستغرق الحقن في أوردتك ما بين 30 ثانية و5 دقائق وستكون الجرعة عادةً 1 ملغم. أكبر جرعة جرانيترون ستُعطى لك هي 3 ملغم يومياً. &nbsp;</p><p>&nbsp;</p><p dir="RTL"><em>يستخدم لدى الأطفال للوقاية من الإعياء أو التقيؤ أو معالجته بعد الجراحة </em></p><p dir="RTL">لا ينبغي إعطاء هذا الحقن للأطفال لعلاج الغثيان أو التقيؤ بعد الجراحة.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا أُعطيت جرانيترون أكثر من اللازم </strong></p><p dir="RTL">من غير المرجح أن تحصل على جرعة زائدة، نظراً لأن يتم إعطاء هذا الحقن أو التسريب من قِبل الطبيب أو الممرض. ومع ذلك، إذا انتابك القلق تحدث إلى طبيبك أو الممرض. تشمل أعراض الجرعة الزائدة نوبات صداع خفيفة. سيتم علاجك وفقاً لأعراضك.</p><p>&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، اسأل الطبيب، الممرض أو الصيدلي.</p><p>&nbsp;</p><p dir="RTL">للحصول على معلومات مخصصة لمتخصصي الرعاية الصحية، يُرجى الاطلاع على القسم الخاص به في الأسفل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبية، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">إذا لاحظت المشكلة التالية، فعليك زيارة طبيب على الفور:</p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;ردود فعل تحسسية (حساسية مفرطة). قد تشمل العلامات تورم الحلق، الوجه، الشفتين والفم، صعوبة في التنفس أو البلع.</li></ul><p>&nbsp;</p><p dir="RTL"><strong><em>الآثار الجانبية الأخرى التي قد تحدث أثناء أخذ هذا الدواء:</em></strong></p><p dir="RTL"><strong>شائعة جداً (تؤثر في أكثر من مستخدم واحد من كل 10 مستخدمين):</strong></p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;صداع</li><li>&nbsp; &nbsp; &nbsp;الإمساك. سيراقب طبيبك حالتك.</li></ul><p>&nbsp;</p><p dir="RTL"><strong>شائعة (تؤثر فيما يصل إلى مستخدم واحد من كل 10 مستخدمين):</strong></p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;صعوبة النوم (الأرق)</li><li>&nbsp; &nbsp; &nbsp;إسهال</li><li>&nbsp; &nbsp; &nbsp;تُظهر فحوصات الدم تغيرات في كيفية عمل الكبد.</li></ul><p dir="RTL"><strong>غير شائعة (تؤثر فيما يصل إلى مستخدم واحد من كل 100 مستخدم):</strong></p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;طفح جلدي أو رد فعل تحسسي جلدي أو &quot;الطفح القراصي&quot; أو &quot;الشرى&quot; (أرتيكاريا). قد تشمل العلامات نتوءات حمراء بارزة ومثيرة للحكة.</li><li>&nbsp; &nbsp; &nbsp;حركات لا إرادية غير طبيعية، مثل الرعشة، تيبس العضلات وانقباضات العضلات</li><li>&nbsp; &nbsp; تغيرات في ضربات القلب (النظم) والتغيرات التي تظهر في قراءات مخطط كهربية القلب (التسجيلات الكهربائية للقلب)</li><li>&nbsp; &nbsp; &nbsp;متلازمة السيروتونين. قد تشمل العلامات إسهال، غثيان، قيء، ارتفاع درجة الحرارة وضغط الدم، فرط التعرق وسرعة ضربات القلب، تهيُّج، ارتباك، هلوسة، رعشة، ارتعاش العضلات، نفضات أو تيبس، فقدان التنسيق والأرق.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أن المحلول غير صافٍ أو غير خالٍ من الجزيئات.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة<strong> </strong>هي هيدروكلوريد الجرانيسيترون.</p><p>&nbsp;</p><p dir="RTL">يحتوي كل مللتر من جرانيترون 1 ملغم/مللتر مركز للتخفيف للحقن/للتسريب على 1.12 ملغم هيدروكلوريد الجرانيسيترون يكافئ 1 ملغم جرانيسيترون.</p><p>&nbsp;</p><p dir="RTL">يحتوي كل 3 مللتر من جرانيترون 3 ملغم/3 مللتر مركز للتخفيف للحقن/للتسريب على 3.36 ملغم هيدروكلوريد الجرانيسيترون يكافئ 3 ملغم جرانيسيترون.</p><p>&nbsp;</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي كلوريد الصوديوم، حمض السيتريك، حمض الهيدروكلوريك، هيدروكسيد الصوديوم وماء معد للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">جرانيترون 1 ملغم/مللتر مركز للتخفيف للحقن/للتسريب هو محلول شفاف وعديم اللون في أمبولات زجاجية مغلقة من النوع رقم واحد مع نقطة كسر واحدة لونها أزرق.</p><p>&nbsp;</p><p dir="RTL">حجم العبوة: 5 أمبولات (1 مللتر).</p><p>&nbsp;</p><p dir="RTL">جرانيترون 3 ملغم/3 مللتر مركز للتخفيف للحقن/للتسريب هو محلول شفاف وعديم اللون في أمبولات زجاجية مغلقة من النوع رقم واحد مع نقطة كسر واحدة لونها برتقالي.</p><p>&nbsp;</p><p dir="RTL">حجم العبوة: 5 أمبولات (3 مللتر).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان </strong><strong>مالك رخصة التسويق </strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">شركة أدوية الحكمة (البرتغال)، العامة المحدودة<br />إسترادا دو ريو دا مو،</p><p dir="RTL">مبنى رقم <img src="data:image/png;base64,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" alt="" width="126" height="26" vspace="0" hspace="0" border="0" style="width:126px;height:26px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" />، فارفانسا<br />2705-906&nbsp;تيروجيم</p><p dir="RTL">سنترا، البرتغال<br />هاتف: 19608410 (2-351) +<br />فاكس: 19615102 (2-351) +</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><p dir="RTL">&nbsp;</p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 2023/02؛ رقم النسخة SA1.1.


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Granitron 1 mg/ml Concentrate for Solution for Injection/Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml contains 1.12 mg granisetron hydrochloride equivalent to 1 mg granisetron. 

Excipients with known effect: Sodium.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for injection/infusion.

Clear and colorless solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Granitron is indicated in adults for the prevention and treatment of</p><ul><li>&nbsp; &nbsp; Acute nausea and vomiting associated with chemotherapy and radiotherapy.</li><li>&nbsp; &nbsp; Post-operative nausea and vomiting.</li></ul><p>Granitron is indicated for the prevention of delayed nausea and vomiting associated with chemotherapy and radiotherapy.</p><p>&nbsp;</p><p>Granitron is indicated in children aged 2 years and above for the prevention and treatment of acute nausea and vomiting associated with chemotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p><em>Chemo- and radiotherapy-induced nausea and vomiting (CINV and RINV)</em></p><p><u>Prevention (acute and delayed nausea and vomiting)</u></p><p>A dose of 1 &ndash; 3 mg (10 &ndash; 40 &micro;g/kg) of Granitron should be administered either as a slow intravenous injection or as a diluted intravenous infusion 5 minutes prior to the start of chemotherapy or radiotherapy. The solution should be diluted to 5 ml per mg.</p><p>&nbsp;</p><p><u>Treatment (acute nausea and vomiting)</u></p><p>A dose of 1 &ndash; 3 mg (10 &ndash; 40 &micro;g/kg) of Granitron should be administered either as a slow intravenous injection or as a diluted intravenous infusion and administered over 5 minutes. The solution should be diluted to 5 ml per mg. Further maintenance doses of Granitron may be administered at least 10 minutes apart. The maximum dose to be administered over 24 hours should not exceed 9 mg.</p><p>&nbsp;</p><p><em>Combination with adrenocortical steroid</em></p><p>The efficacy of parenteral granisetron may be enhanced by an additional intravenous dose of an adrenocortical steroid e.g. by 8 - 20 mg dexamethasone administered before the start of the cytostatic therapy or by 250 mg methyl-prednisolone administered prior to the start and shortly after the end of the chemotherapy.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of granisetron in children aged 2 years and above has been well established for the prevention and treatment (control) of acute nausea and vomiting associated with chemotherapy. A dose of 10 &ndash; 40 &micro;g/kg body weight (up to 3 mg) should be administered as an IV infusion, diluted in 10 - 30 ml infusion fluid and administered over 5 minutes prior to the start of chemotherapy. One additional dose may be administered within a 24 hour-period if required. This additional dose should not be administered until at least 10 minutes after the initial infusion.</p><p>&nbsp;</p><p><em>Post-operative nausea and vomiting (PONV)</em></p><p>A dose of 1 mg (10 &micro;g/kg) of Granitron should be administered by slow intravenous injection. The maximum dose of Granitron to be administered over 24 hours should not exceed 3 mg.</p><p>&nbsp;</p><p>For the prevention of PONV, administration should be completed prior to induction of anaesthesia.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Currently available data are described in section 5.1, but no recommendation on a posology can be made. There is insufficient clinical evidence to recommend administration of the solution for injection to children in prevention and treatment of post-operative nausea and vomiting.</p><p>&nbsp;</p><p><em>Special populations</em></p><p><u>Elderly and renal impairment</u></p><p>There are no special precautions required for its use in either elderly patients or those patients with renal or hepatic impairment.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>There is no evidence to date for an increased incidence of adverse events in patients with hepatic disorders. On the basis of its kinetics, whilst no dosage adjustment is necessary, granisetron should be used with a certain amount of caution in this patient group (see section 5.2).</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>Administration may be as either a slow intravenous injection (over 30 seconds) or as an intravenous infusion diluted in 20 - 50 ml infusion fluid and administered over 5 minutes.</p><p>&nbsp;</p><p>For instructions on dilution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As granisetron may reduce lower bowel motility, patients with signs of sub-acute intestinal obstruction should be monitored following its administration.</p><p>&nbsp;</p><p>As for other 5-HT3 antagonists, ECG changes including QT interval prolongation have been reported with granisetron. In patients with pre-existing arrhythmias or cardiac conduction disorders this might lead to clinical consequences. Therefore caution should be exercised in patients with cardiac co-morbidities, on cardiotoxic chemotherapy and/or with concomitant electrolyte abnormalities (see section 4.5).</p><p>&nbsp;</p><p>Cross-sensitivity between 5-HT3 antagonists (e.g. dolasetron, ondansetron) has been reported.</p><p>&nbsp;</p><p><strong>Serotonin syndrome</strong></p><p>There have been reports of serotonin syndrome with the use of 5-HT<sub>3</sub>&nbsp;antagonists either alone, but mostly in combination with other serotonergic drugs (including selective serotonin reuptake inhibitors (SSRIs), and serotonin noradrenaline reuptake inhibitors (SNRIs). Appropriate observation of patients for serotonin syndrome-like symptoms is advised.</p><p>&nbsp;</p><p><strong>Granitron contains sodium </strong></p><p>Granitron contains sodium. Each ml contains 3.542 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per ampoule, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As for other 5-HT3 antagonists, cases of ECG modifications including QT prolongation have been reported with granisetron. In patients concurrently treated with medicinal products known to prolong QT interval and/or which are arrhythmogenic, this may lead to clinical consequences (see section 4.4).</p><p>&nbsp;</p><p>In humans, hepatic enzyme induction with phenobarbital resulted in an increase in total plasma clearance of granisetron of approximately 25%.</p><p>&nbsp;</p><p>In studies in healthy subjects, no evidence of any interaction has been indicated between granisetron and benzodiazepines (lorazepam), neuroleptics (haloperidol) or anti-ulcer medicinal products (cimetidine). Additionally, granisetron has not shown any apparent medicinal product interaction with emetogenic cancer chemotherapies.</p><p>&nbsp;</p><p>No specific interaction studies have been conducted in anaesthetised patients.</p><p>&nbsp;</p><p><strong>Serotonergic medicinal products (e.g. SSRIs and SNRIs)</strong></p><p>There have been reports of serotonin syndrome following concomitant use of 5-HT<sub>3</sub>&nbsp;antagonists and other serotonergic medicinal products (including SSRIs and SNRIs) (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>There is limited amount of data from the use of granisetron in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of granisetron during pregnancy.</p><p>&nbsp;</p><p><strong>Breastfeeding</strong></p><p>It is unknown whether granisetron or its metabolites are excreted in human milk. As a precautionary measure, breastfeeding should not be advised during treatment with Granitron.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>In rats, granisetron had no harmful effects on reproductive performance or fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Granisetron has no or negligible influence on the ability to drive or to use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong></p><p>The most frequently reported adverse reactions for granisetron are headache and constipation which may be transient. ECG changes including QT prolongation have been reported with granisetron (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p><strong>Tabulated summary of adverse reactions</strong></p><p>The following table of listed adverse reactions is derived from clinical trials and post-marketing data associated with granisetron and other 5-HT<sub>3&nbsp;</sub>antagonists.</p><p>&nbsp;</p><p>Frequency categories are as follows:</p><p>Very common: (&ge;1/10)</p><p>Common (&ge;1/100 to &lt;1/10)</p><p>Uncommon (&ge;1/1,000 to &lt;1/100)</p><p>Rare (&ge;1/10,000 to &lt;1/1,000)</p><p>Very rare (&lt;1/10,000)</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p><em>Uncommon</em></p><p>Hypersensitivity reactions e.g. anaphylaxis, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p><em>Common</em></p><p>Insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p><em>Very Common</em></p><p>Headache</p><p><em>Uncommon</em></p><p>Extrapyramidal reactions, Serotonin syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p><em>Uncommon</em></p><p>QT interval prolonged</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p><em>Very common</em></p><p>Constipation</p><p><em>Common</em></p><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p><em>Common</em></p><p>Transaminases increased*</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p><em>Uncommon</em></p><p>Rash</p></td></tr></tbody></table><p>*Occurred at a similar frequency in patients receiving comparator therapy.</p><p><strong>&nbsp;</strong></p><p><strong>Description of selected adverse reactions</strong></p><p>As for other 5-HT<sub>3</sub>&nbsp;antagonists, ECG changes including QT prolongation have been reported with granisetron (see sections 4.4 and 4.5).</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>&nbsp; &nbsp; Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><ul><li>&nbsp; &nbsp; Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific antidote for granisetron. In the case of overdose with the injection or infusion, symptomatic treatment should be given. Doses of up to 38.5 mg of granisetron as a single injection have been reported, with symptoms of mild headache but no other reported sequelae.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antiemetics and antinauseants, Serotonin (5-HT<sub>3</sub>) antagonists.</p><p>&nbsp;</p><p>ATC code: A04AA02</p><p><strong>&nbsp;</strong></p><p><strong>Neurological mechanisms, serotonin-mediated nausea and vomiting</strong></p><p>Serotonin is the main neurotransmitter responsible for emesis after chemo- or radiotherapy. The 5-HT<sub>3</sub>&nbsp;receptors are located in three sites: vagal nerve terminals in the gastrointestinal tract and chemoreceptor trigger zones located in the&nbsp;<em>area postrema</em>&nbsp;and the&nbsp;<em>nucleus tractus solidarius</em>&nbsp;of the vomiting centre in the brainstem. The chemoreceptor trigger zones are located at the caudal end of the fourth ventricle (<em>area postrema</em>). This structure lacks an effective blood-brain barrier, and will detect emetic agents in both the systemic circulation and the cerebrospinal fluid. The vomiting centre is located in the brainstem medullary structures. It receives major inputs from the chemoreceptor trigger zones, and a vagal and sympathetic input from the gut.</p><p>&nbsp;</p><p>Following exposure to radiation or cytotoxic substances, serotonin (5-HT) is released from enterochromaffine cells in the small intestinal mucosa, which are adjacent to the vagal afferent neurons on which 5-HT<sub>3</sub>&nbsp;receptors are located. The released serotonin activates vagal neurons via the 5-HT<sub>3</sub>&nbsp;receptors which lead ultimately to a severe emetic response mediated via the chemoreceptor trigger zone within the<em>&nbsp;area postrema</em>.</p><p>&nbsp;</p><p><strong>Mechanism of action</strong></p><p>Granisetron is a potent antiemetic and highly selective antagonist of 5-hydroxytryptamine (5 HT<sub>3</sub>) receptors. Radioligand binding studies have demonstrated that granisetron has negligible affinity for other receptor types including 5-HT and dopamine D<sub>2</sub>&nbsp;binding sites.</p><p>&nbsp;</p><p><u>Chemotherapy- and radiotherapy-induced nausea and vomiting</u></p><p>Granisetron administered intravenously has been shown to prevent nausea and vomiting associated with cancer chemotherapy in adults and children 2 - 16 years of age.</p><p>&nbsp;</p><p><u>Post-operative nausea and vomiting</u></p><p>Granisetron administered intravenously has been shown to be effective for prevention and treatment of post-operative nausea and vomiting in adults.</p><p><strong>&nbsp;</strong></p><p><strong>Pharmacological properties of granisetron</strong></p><p>Interaction with neurotropic and other active substances through its activity on P 450-cytochrome has been reported (see section 4.5).</p><p><em>&nbsp;</em></p><p><em>In vitro</em>&nbsp;studies have shown that the cytochrome P450 subfamily 3A4 (involved in the metabolism of some of the main narcotic agents) is not modified by granisetron. Although ketoconazole was shown to inhibit the ring oxidation of granisetron&nbsp;<em>in vitro</em>, this action is not considered clinically relevant.</p><p>&nbsp;</p><p>Although QT prolongation has been observed with 5-HT<sub>3</sub>&nbsp;receptors antagonists (see section 4.4), this effect is of such occurrence and magnitude that it does not bear clinical significance in normal subjects. Nonetheless it is advisable to monitor both ECG and clinical abnormalities when treating patients concurrently with medicinal products known to prolong the QT (see section 4.5).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Clinical application of granisetron was reported by Candiotti et al. A prospective, multicentre, randomized, double-blind, parallel-group study evaluated 157 children 2 to 16 years of age undergoing elective surgery. Total control of post-operative nausea and vomiting during the first 2 hours after surgery was observed in most patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetics of the oral administration is linear up to 2.5-fold of the recommended dose in adults. It is clear from the extensive dose-finding programme that the antiemetic efficacy is not unequivocally correlated with either administered doses or plasma concentrations of granisetron.</p><p>&nbsp;</p><p>A fourfold increase in the initial prophylactic dose of granisetron made no difference in terms of either the proportion of patient responding to treatment or in the duration of symptom control.</p><p><strong>&nbsp;</strong></p><p><strong>Distribution</strong></p><p>Granisetron is extensively distributed, with a mean volume of distribution of approximately 3 l/kg. Plasma protein binding is approximately 65%.</p><p><strong>&nbsp;</strong></p><p><strong>Biotransformation</strong></p><p>Granisetron is metabolized primarily in the liver by oxidation followed by conjugation. The major compounds are 7-OH-granisetron and its sulphate and glycuronide conjugates. Although antiemetic properties have been observed for 7-OH-granisetron and indazoline N-desmethyl granisetron, it is unlikely that these contribute significantly to the pharmacological activity of granisetron in man.&nbsp;<em>In vitro</em>&nbsp;liver microsomal studies show that granisetron&#39;s major route of metabolism is inhibited by ketoconazole, suggestive of metabolism mediated by the cytochrome P 450 3A subfamily.</p><p><strong>&nbsp;</strong></p><p><strong>Elimination</strong></p><p>Clearance is predominantly by hepatic metabolism. Urinary excretion of unchanged granisetron averages 12% of dose while that of metabolites amounts to about 47% of dose. The remainder is excreted in faeces as metabolites. Mean plasma half-life in patients by the oral and intravenous route is approximately 9 hours, with a wide inter-subject variability.</p><p><strong>&nbsp;</strong></p><p><strong>Pharmacokinetics in special populations</strong></p><p><em>Renal failure</em></p><p>In patients with severe renal failure, data indicate that pharmacokinetic parameters after a single intravenous dose are generally similar to those in normal subjects.</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p>In patients with hepatic impairment due to neoplastic liver involvement, total plasma clearance of an intravenous dose was approximately halved compared to patients without hepatic involvement. Despite these changes, no dosage adjustment is necessary (see section 4.2).</p><p><em>&nbsp;</em></p><p><em>Elderly patients</em></p><p>In elderly subjects after single intravenous doses, pharmacokinetic parameters were within the range found for non-elderly subjects.</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>In children, after single intravenous doses, pharmacokinetics are similar to those in adults when appropriate parameters (volume of distribution, total plasma clearance) are normalized for body weight.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, reproductive toxicity and genotoxicity. Carcinogenicity studies revealed no special hazard for humans when used in the recommended human dose. However, when administered in higher doses and over a prolonged period of time the risk of carcinogenicity cannot be ruled out.</p><p>&nbsp;</p><p>A study in cloned human cardiac ion channels has shown that granisetron has the potential to affect cardiac repolarisation via blockade of HERG potassium channels. Granisetron has been shown to block both sodium and potassium channels, which potentially affects both depolarization and repolarization through prolongation of PR, QRS, and QT intervals. This data helps to clarify the molecular mechanisms by which some of the ECG changes (particularly QT and QRS prolongation) associated with this class of agents occur. However, there is no modification of the cardiac frequency, blood pressure or the ECG trace. If changes do occur, they are generally without clinical significance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; Sodium chloride</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Citric acid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Hydrochloric acid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Sodium hydroxide</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.

The product should be used immediately after opening. For single use only. Discard any remaining portion.

Shelf life after Dilution:
Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C in normal indoor illumination protected from direct sunlight. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2-8°C, unless dilution has taken place in controlled and validated aseptic conditions

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I clear sealed glass ampoules with blue one point cut (OPC).</p><p>&nbsp;</p><p>Pack size: 5 Ampoules (1 ml).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Preparing the infusion</strong></p><p><em>Adults:</em> The contents of a 1 ml ampoule can be diluted to a volume of 5 ml; the contents of a 3 ml ampoule can be diluted to a volume of 15 ml.</p><p>&nbsp;</p><p>Granitron can also be diluted in 20 - 50 ml compatible infusion fluid and then given over 5 minutes as an intravenous infusion in any of the following solutions:</p><ul><li>&nbsp; &nbsp; 0.9% Sodium chloride solution</li><li>&nbsp; &nbsp; 5% Dextrose solution</li><li>&nbsp; &nbsp; 0.18% Sodium chloride and 4% dextrose solution</li></ul><p>&nbsp;</p><p>No other diluents should be used.</p><p>&nbsp;</p><p><em>Children 2 years of age and older</em>: To prepare the dose of 10 - 40 &micro;g/kg, the appropriate volume is withdrawn and diluted with infusion fluid (as for adults) to a total volume of 10 - 30 ml.</p><p>&nbsp;</p><p>As a general precaution, Granitron should not be mixed in solution with other drugs</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                28 February 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>